Edible blended oil and application thereof

Abstract

The invention discloses an edible blended oil and an application thereof. The edible blended oil comprises, calculated by weight percentage of each raw material, 20-40% of medium-chain triglycerides, 20-60% of olive oil, 5-20% of fish oil, 2-10% of pomegranate seed oil, 2.5-10% of torreya grandis seed oil and 5-13% of linseed oil; wherein the edible blended oil has an irritant aldehyde content of 40.2-120.5 mg / kg, a hydroxytyrosol content of 77.6-232.8 mg / kg, an oleuropein content of 180-540 mg / kg, a punicalagin content of 4.2-20.03 mg / kg, an ellagic acid content of 8.01-40.2 mg / kg, a quercetin content of 7.02-35.1 mg / kg, a tocopherol content of 113.6-162.8 mg / kg and a lignan content of 130.7-338 mg / kg. The blended oil of the present invention is reasonably formulated, easy to digest and absorb, has the characteristics of preventing and / or delaying the recurrence of breast cancer, and is helpful for the postoperative recovery of breast cancer patients.

Description

Technical Field

[0001] The invention belongs to the technical field of special medical formula foods, and in particular relates to an edible blended oil and an application thereof. Background Art

[0002] Breast Cancer (BC) is a malignant tumor that occurs in the mammary epithelium or ductal epithelium and is one of the most common malignant tumors in women worldwide. Breast cancer is divided into luminal A, luminal B, HER-2 overexpression and basal-like types based on differences in gene expression profiles.

[0003] At present, there are 1.7 million new cases of breast cancer worldwide each year, accounting for about one-tenth of all malignant tumors in the body, and it is the leading malignant tumor in women. The pathogenesis of breast cancer is still unclear, but a large number of studies have shown that the onset of breast cancer involves many causes, among which dietary habits have a profound impact on the occurrence and development of breast cancer.

[0004] Olive oil is a major component of the Mediterranean diet. Because extra virgin olive oil is rich in phenolic substances and monounsaturated fatty acids, regular consumption can reduce the risk of breast cancer. Some randomized clinical trials on the effects of long-term dietary intervention on the incidence of breast cancer have shown that a Mediterranean diet supplemented with extra virgin olive oil is beneficial for the primary prevention of breast cancer. Oleuropein, hydroxytyrosol, and oleuropein are polyphenolic compounds with strong antioxidant properties and good biological effects. As important phenolic substances in olive oil, they play an important role in the prevention and treatment of breast cancer.

[0005] A large number of studies have shown that linolenic acid in flaxseed oil, w-3 fatty acids in fish oil, and paclitaxel in Torreya grandis seed oil have inhibitory effects on the malignant biological behavior of breast cancer cell lines by inhibiting the relevant signal pathways of breast cancer cell migration and invasion ability.

[0006] Therefore, preparing an edible blended oil from dietary lipids can not only play a fundamental role in preventing and / or delaying the recurrence of breast cancer (BC), but also will not bring any potential safety risks to breast cancer patients (BC), and is low-cost and easily available.

[0007] At present, special nutritional formulas for breast cancer patients in the domestic market are in the early stages of research and development, and the restrictions on the amount and type of fat intake for preventing breast cancer are relatively rough.

[0008] Therefore, combining the fatty acid composition and beneficial functional ingredients of olive oil to prepare an edible blended oil suitable for preventing breast cancer is a technical problem that needs to be urgently solved in the field. Summary of the invention

[0009] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.

[0010] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.

[0011] Therefore, the object of the present invention is to overcome the deficiencies in the prior art and provide an edible blended oil.

[0012] In order to solve the above technical problems, the present invention provides the following technical solutions: an edible blended oil, wherein the edible blended oil, calculated by weight percentage of each raw material, comprises 20-40% medium chain triglycerides, 20-60% olive oil, 5-20% fish oil, 2-10% pomegranate seed oil, 2.5-10% torreya seed oil and 5-13% linseed oil;

[0013] The edible blended oil contains 40.2-120.5 mg / kg of irritant aldehyde, 77.6-232.8 mg / kg of hydroxytyrosol, 180-540 mg / kg of oleuropein, 4.2-20.03 mg / kg of punicalagin, 8.01-40.2 mg / kg of ellagic acid, 7.02-35.1 mg / kg of quercetin, 113.6-162.8 mg / kg of tocopherol and 130.7-338 mg / kg of lignans.

[0014] As a preferred embodiment of the edible blended oil of the present invention, the edible blended oil has an irritant aldehyde content of 85.4±0.22 mg / kg, a hydroxytyrosol content of 164.9±0.5 mg / kg, an oleuropein content of 382.5±3.21 mg / kg, a punicalagin content of 10.1±0.04 mg / kg, an ellagic acid content of 20.3±0.06 mg / kg, a quercetin content of 17.55±0.07 mg / kg, a tocopherol content of 142.7±0.3 mg / kg, and a lignan content of 195.4±0.22 mg / kg.

[0015] As a preferred embodiment of the edible blended oil of the present invention, the edible blended oil comprises 17%-48% oleic acid, 1.6-8% punicic acid, 0.33-1.3% succinic acid, 5.8-11% linolenic acid, 1-4% EPA and 0.75-3% DHA.

[0016] As a preferred embodiment of the edible blended oil of the present invention, the oleic acid content is 38.3%, the punicic acid content is 4%, the saponin content is 0.65%, the linolenic acid content is 7%, the EPA content is 1.5%, and the DHA content is 1.12%.

[0017] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for preparing an edible blended oil, comprising mixing edible medium-chain triglycerides, olive oil, fish oil, pomegranate seed oil, Torreya grandis seed oil and linseed oil, stirring and filtering to obtain the edible blended oil.

[0018] As a preferred embodiment of the method for preparing edible blended oil of the present invention, the stirring temperature is room temperature, the stirring time is 20 to 30 minutes, and the stirring speed is 60 to 80 r / min.

[0019] As a preferred embodiment of the method for preparing edible blended oil of the present invention, the filtration is performed through a 400-mesh net.

[0020] As a preferred embodiment of the method for preparing edible blended oil of the present invention, the edible blended oil, calculated by weight percentage of each raw material, comprises 20-40% medium chain triglycerides, 20-60% olive oil, 5-20% fish oil, 2-10% pomegranate seed oil, 2.5-10% torreya seed oil and 5-13% linseed oil.

[0021] As a preferred embodiment of the method for preparing the edible blended oil of the present invention, the edible blended oil has an irritant aldehyde content of 40.2-120.5 mg / kg, a hydroxytyrosol content of 77.6-232.8 mg / kg, an oleuropein content of 180-540 mg / kg, a punicalagin content of 4.2-20.03 mg / kg, an ellagic acid content of 8.01-40.2 mg / kg, a quercetin content of 7.02-35.1 mg / kg, a tocopherol content of 113.6-162.8 mg / kg, and a lignan content of 130.7-338 mg / kg.

[0022] Another object of the present invention is to overcome the deficiencies in the prior art and provide an application of an edible blended oil in the preparation of a special medical formula food for preventing the occurrence and development of breast cancer, wherein the breast cancer includes triple-negative breast cancer, triple-positive breast cancer and Her-2 overexpressing breast cancer.

[0023] Beneficial effects of the present invention:

[0024] (1) The good fatty acid composition of the fat component of the present invention can quickly provide energy, induce the generation of reactive oxygen species (ROS), and promote cell apoptosis; the blended oil of the present invention contains rich olive polyphenols, such as irritant aldehyde, hydroxytyrosol, oleuropein and other phenolic substances, which are strong antioxidants in olive oil and will generate a large amount of reactive oxygen species through self-oxidation, directly attack tumor cells, inhibit cell proliferation through the PI3K / AKT pathway, promote cell cycle arrest, and initiate apoptosis, ultimately achieving the effect of inhibiting tumor growth; ellagic acid, punicalagin and quercetin in pomegranate seed oil all have anti-tumor and antibacterial activities. However, only when the content of irritating aldehyde is within the range of 40.2-120.5mg / kg, hydroxytyrosol content is within the range of 116.4-194mg / kg, oleuropein content is within the range of 180-540mg / kg, punicalagin 4.2-20.03mg / kg, ellagic acid 8.01-40.2mg / kg, quercetin 7.02-35.1mg / kg, tocopherol 113.6-162.8mg / kg and lignan 130.7-338mg / kg, can it have the effect of inhibiting the growth of breast cancer cells and inhibiting the cell cycle; beyond this range, the effect is not good, which may be due to the synergistic effect of polyphenols and fatty acids within a certain concentration range, and beyond this range, the synergistic effect may disappear or produce antagonism, resulting in poor effect in inhibiting the growth of breast cancer cells.

[0025] (2) The blended oil of the present invention is reasonably formulated, easy to digest and absorb, has the characteristics of preventing and / or delaying the recurrence of breast cancer, and is helpful for the postoperative recovery of breast cancer patients; the present invention does not contain any antioxidants and is blended from pure natural edible oil.

[0026] (3) The blended oil of the present invention can be used as a fat component of a specific complete nutritional formula food for special medical purposes for breast cancer patients, and can also be used as a fat component in a nutrient group of a non-complete nutritional formula food for breast cancer patients, and can be used in combination with other special medical formula foods or ordinary foods. The use of the blended oil of the present invention will not bring any potential safety hazards to breast cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:

[0028] Figure 1 Graph showing the effect of blended oil on the activity of MCF-7 breast cancer cells in an embodiment of the present invention.

[0029] Figure 2Graph showing the effect of blended oil on the production of reactive oxygen species (ROS) in MCF-7 breast cancer cells in an example of the present invention.

[0030] Figure 3 Graph showing the effect of blended oil on the cell cycle distribution of MCF-7 breast cancer cells in an embodiment of the present invention.

[0031] Figure 4 This is a graph showing the effect of blended oil on apoptosis of MCF-7 breast cancer cells in an example of the present invention.

[0032] Figure 5 Graph showing the effect of blended oil on the cell cycle pathway of MCF-7 breast cancer cells in an embodiment of the present invention. DETAILED DESCRIPTION

[0033] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.

[0034] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0035] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.

[0036] The MTT kit for detecting cell activity, Annexin V-FITC / PI apoptosis kit, and cell cycle kit involved in the following examples were purchased from Lianke Biotechnology Co., Ltd.

[0037] The raw materials in the present invention are all common commercially available products.

[0038] Each effective ingredient and its function in the present invention:

[0039] Medium-chain triglycerides can provide energy to the body quickly and efficiently through the portal vein; oleic acid in olive oil can increase the expression of p27Kip1 protein (tumor suppressor protein); w-3 polyunsaturated fatty acids in fish oil mainly activate fatty acid oxidation pathways by inhibiting glycolysis and glutamine metabolism pathways, thereby causing the accumulation of ROS and promoting tumor cell death; pomegranate seed oil can significantly downregulate the expression levels of Cox-2 and Bcl-2 in cells, and upregulate the expression levels of Bax and caspase-3 (enzymatic hydrolysis) to promote cell apoptosis; the linolenic acid contained in flaxseed oil also has an inhibitory effect on the spontaneous metastasis of breast cancer tumors.

[0040] Fat components are rich in polyphenols. Phenolic substances such as irritant aldehyde, hydroxytyrosol, oleuropein, punicalagin, ellagic acid, quercetin, tocopherol, etc. are strong antioxidants in edible oils. They will self-oxidize to generate a large amount of reactive oxygen species, directly attack tumor cells, inhibit tumor cell proliferation through the PI3K / AKT pathway, promote cell cycle arrest, initiate apoptosis, and ultimately achieve the effect of inhibiting tumors. The Mediterranean diet rich in olive oil has a negative correlation with the occurrence of breast cancer. To a certain extent, a diet rich in olive oil can play a primary prevention role in breast cancer.

[0041] Example 1

[0042] Blending oil: 40% high-quality edible medium-chain triglycerides, 20% extra virgin olive oil, 20% fish oil, 2% pomegranate seed oil, 10% Torreya grandis seed oil and 8% refined linseed oil are added into the reactor.

[0043] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0044] Example 2

[0045] Blending oil: 40% high-quality edible medium-chain triglycerides, 20% extra virgin olive oil, 15% fish oil, 3% pomegranate seed oil, 9% Torreya grandis seed oil and 13% refined linseed oil are added into the reactor.

[0046] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0047] Example 3

[0048] Blending oil: 35% high-quality edible medium-chain triglycerides, 25% extra virgin olive oil, 10% fish oil, 10% pomegranate seed oil, 10% Torreya grandis seed oil and 10% refined linseed oil are added into the reactor.

[0049] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0050] Example 4

[0051] Blending oil: 32.5% high-quality edible medium-chain triglycerides, 42.5% extra virgin olive oil, 7.5% fish oil, 5% pomegranate seed oil, 5% Torreya grandis seed oil and 7.5% refined linseed oil are added into the reactor.

[0052] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0053] Example 5

[0054] Blending oil: 32.5% high-quality edible medium-chain triglycerides, 42.5% extra virgin olive oil, 5% fish oil, 7.5% pomegranate seed oil, 7.5% Torreya grandis seed oil and 5% refined linseed oil are added into the reactor.

[0055] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0056] Example 6

[0057] Blending oil: 20% high-quality edible medium-chain triglycerides, 60% extra virgin olive oil, 5% fish oil, 5% pomegranate seed oil, 5% Torreya grandis seed oil and 5% refined linseed oil are added into the reactor.

[0058] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0059] Example 7

[0060] Blending oil: 20% high-quality edible medium-chain triglycerides, 60% extra virgin olive oil, 5% fish oil, 2.5% pomegranate seed oil, 2.5% Torreya grandis seed oil and 10% refined linseed oil are added into the reactor.

[0061] The mixture was mixed at room temperature (25°C) and stirred for 20 minutes at a stirring speed of 50 r / min. After the stirring, the mixed oil was filtered through a 400-mesh net to obtain the mixed oil, which was then digested in vitro to obtain the digestion product.

[0062] Comparative Example 1

[0063] Blended oil: As in Example 4, except that the blended oil needs to be treated with a silica gel column to remove polyphenols in the blended oil.

[0064] Silica gel column: Weigh 50g of 0.5-0.75mm silica gel and activate it in a 125℃ oven for 3h, then cool it to room temperature in a desiccator; connect the lower end of a fixed chromatography column (Φ25mm×300mm, 100mL) to the collector. Use wet filling and wet loading.

[0065] In vitro digestion parameters: 5 g of oil was mixed with 5 mL of porcine α-amylase, incubated in a shaker at 37°C for 5 min, then 10 mL of simulated gastric fluid was added, the pH was adjusted to 3.0 with hydrochloric acid, porcine pepsin was added, and the mixture was incubated in a shaker for 120 min. Then 10 mL of intestinal fluid and 5 mL of bile salts were added, the pH was adjusted to 7.0, pancreatic enzyme was added, and the mixture was incubated in a shaker for 120 min to obtain the digestion product.

[0066] The fatty acid composition and oil accompanying substances of the obtained blended oil were detected and analyzed, as shown in Table 1-1.

[0067] Table 1-1 The percentage of the main fatty acids and the content of trace accompaniments in each embodiment (mg / kg)

[0068]

[0069]

[0070] ND stands for Not Detected

[0071] In vitro digestion experiment of the present invention:

[0072] Breast cancer cell culture:

[0073] 1. Recovery: Take out the cell cryopreservation tube from the liquid nitrogen tank quickly, place it in a 37℃ water bath for rapid thawing, add culture medium, and culture it in a 37℃ incubator;

[0074] 2. Passaging: Cells are passaged when the cell confluence reaches 90%.

[0075] Administration and dosage of breast cancer cells:

[0076] After 24 hours of cell culture, the cells were treated with the digestion products of different examples for 24 hours, respectively, and were set as Example 1 group, Example 2 group, Example 3 group, Example 4 group, Example 5 group, Example 6 group, Example 7 group, and Comparative Example 1 group.

[0077] The cell survival rate was determined by MTT method, the cell cycle was determined by flow cytometry, the cell apoptosis was determined by flow cytometry and inverted fluorescence microscopy, the cell migration and ROS accumulation were observed by inverted microscopy, and the expression of genes related to the cell cycle pathway was quantified by q-PCR.

[0078] Effects of blended oil on breast cancer cell activity:

[0079] The assay was performed using a 96-well plate, MTT kit, and microplate reader.

[0080] 100 μL of cell culture medium (≥10,000 cells / 100 μL) was added to each well and placed in a 37°C incubator for 24 hours, and then the digestion product of appropriate concentration was added and cultured for another 24 hours. After 24 hours of culture, 50 μL of MTT solution was added to each well in the dark, and after 4 hours of incubation, 150 μL of DMSO was added and the absorbance was detected at 570 nm.

[0081] Depend on Figure 1 It can be seen that Example 4 and Example 5 affect the survival rate of cells, making the survival rate of cells about 80%, and have a certain toxic effect on breast cancer cells. In contrast, Example 1, Example 7, and Comparative Example 1 have less toxic effects on cells, and the cell survival rate is about 93%.

[0082] Effect of blended oil on the content of reactive oxygen species (ROS) in breast cancer cells:

[0083] The logarithmic phase cells were plated on a black bottom 96-well plate. When the cells grew to 70%-80%, the culture medium was discarded and washed twice with PBS. Then a positive control group and a sample group were set up and treated for 6 hours. After discarding the supernatant and washing twice with PBS, DCFH-DA was diluted with DMEM to a final concentration of 10μM. After treatment for 30 minutes, the fluorescence intensity was detected using a fluorescence microplate reader (SpectraMax iD5) at an excitation wavelength of 488nm and an emission wavelength of 525nm.

[0084] Reactive oxygen is a natural byproduct of aerobic respiration and metabolism in aerobic cells, and has an important influence on cell signal transduction and maintaining the stability of the cell's internal environment.

[0085] Example 4 can significantly increase the level of ROS in breast cancer cells and promote tumor cell death. It also reflects that the blended oil in Example 4 is closely related to cell metabolism, cell cycle arrest and cell apoptosis.

[0086] Example 8

[0087] Effects of blended oil on breast cancer cell cycle:

[0088] After 24 hours of drug administration, DNA staining solution and permeabilization solution were added to each group of MCF-7 breast cancer cells, incubated at room temperature in the dark for 5 minutes, and detected by flow cytometry.

[0089] Depend on Figure 3 It can be seen from the MCF-7 cell cycle experiment that the cell cycle of Example 4 group was mainly blocked in the G1 phase, while the proportion of the cell cycle G2 phase of Example 1 group and Comparative Example 1 group was higher than that of other example groups, indicating that the cell process was faster than that of other implementation groups; Example 3 group, Example 6 group, and Example 7 group more obviously blocked the cells in the S phase, and their cell cycle blocking effect was better than that of Example 1 and Comparative Example 1, but weaker than that of Example 4 group.

[0090] The above results indicate that Example 4 can inhibit the proliferation of breast cancer cells by blocking the cells in the G0 / G1 phase, preventing the cells from entering the S phase, and delaying the progression of the cells.

[0091] Effect of blended oil on apoptosis of breast cancer cells:

[0092] 24 hours after administration, breast cancer cells in each group were stained with Annexin V-FITC and PI, vortexed for 5-10 seconds, mixed, incubated at room temperature in the dark for 30 minutes, and detected by flow cytometry.

[0093] Depend on Figure 4 It can be seen that the MCF-7 flow cell apoptosis graph shows that the early apoptosis ratios of Example 4 and Example 5 are the largest, which are 11.5% and 20.4% respectively, while the early apoptosis ratios of Example 1, Example 7 and Comparative Example 1 are 2.22%, 3.16% and 2.61% respectively. It can be concluded that Example 4 and Example 5 can significantly promote early apoptosis of cells. The fluorescent apoptosis graph can also intuitively show that Example 4 and Example 5 can significantly promote early apoptosis and late apoptosis of cells, while only a few cells in Example 1, Example 7 and Comparative Example 1 are stained, and the effect on cell apoptosis is not significant.

[0094] Effects of blended oil on breast cancer cell cycle pathways:

[0095] The MCF-7 cells were passaged, cultured for 24 hours, and then the digestion products of different embodiments and comparative examples were given to the cells when they were stable. After another 24 hours of culture, the cells were digested and centrifuged to collect the cells, and a cell RNA extraction reagent was added to extract RNA. The extracted RNA was reverse transcribed into cDNA, and then real-time fluorescence quantitative PCR was performed on CyclinD, CyclinE, CDK2, CDK4, E2F, and Rb genes related to the cell cycle.

[0096] Depend on Figure 5 It can be seen that, taking the gene expression level of 1 in the negative control group as the benchmark, the relative expression levels of CyclinD, CyclinE, CDK2, and CDK4 genes in Examples 3, 4, 5, and 6 were all down-regulated.

[0097] There was no significant difference between Example 1, Example 7, Comparative Example 1 and the negative control group. CyclinD binds to CDK4 to regulate the G1 phase of the cell cycle, and CDK2 binds to CyclinE to trigger cells to enter the S phase. In tumor cells, due to their own rapid proliferation, cell cycle proteins are abnormally active, and cell cycle protein kinases bind to cell cycle proteins to exert their activity, which together accelerates the process of the cell cycle, shortens the cell cycle, and thus shortens the time of cell proliferation.

[0098] After the digestion products of Example 4 and Example 5 were administered, the expression levels of cell cycle proteins and cell cycle protein kinase genes were significantly reduced, indicating that Example 4 and Example 5 can inhibit the expression of related genes in the MCF-7 cell cycle pathway, thereby blocking the progression of the cell cycle and inhibiting the proliferation of MCF-7 cells.

[0099] Rb is a tumor suppressor gene that controls the transition from G1 phase to S phase by forming a complex with the transcription factor E2F. The E2F gene itself binds to the Rb protein and does not play a role in the cell cycle, but when CyclinD forms a complex with CDK4, it promotes phosphorylation of Rb, thereby releasing the bound E2F, and E2F activates the S phase gene to advance the cell cycle. Compared with the control group, the expression of the Rb gene was upregulated after administration, and the activity of E2F was also reduced, indicating that Example 4 and Example 5 groups played a role in inhibiting the cell cycle from entering the S phase.

[0100] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the claims of the present invention.

Claims

1. An edible blended oil, characterized in that: The edible blended oil raw materials are composed of medium-chain triglycerides, olive oil, fish oil, pomegranate seed oil, torreya grandis seed oil and linseed oil; Calculated by weight percentage of each raw material, medium chain triglycerides 32.5%, olive oil 42.5%, fish oil 5-7.5%, pomegranate seed oil 5-7.5%, Torreya grandis seed oil 5-7.5% and linseed oil 5-7.5%; The edible blended oil has a content of irritant aldehyde of (85.4±0.22) mg / kg, a content of hydroxytyrosol of (164.9±0.5) mg / kg, a content of oleuropein of (382.5±3.21) mg / kg, a content of punicalagin of (10.1±0.04)~(15±0.08) mg / kg, a content of ellagic acid of (20.3±0.06)~(30.04±0.25) mg / kg, a content of quercetin of (17.55±0.07)~(26.32±0.1) mg / kg, a content of tocopherol of (138.5±0.17)~(142.75±0.3) mg / kg, and a content of lignan of (130.7±0.15)~(195.4±0.22) mg / kg.

2. The edible blended oil according to claim 1, characterized in that: The edible blended oil has a content of (85.4±0.22) mg / kg of irritant aldehyde, a content of (164.9±0.5) mg / kg of hydroxytyrosol, a content of (382.5±3.21) mg / kg of oleuropein, a content of (10.1±0.04) mg / kg of punicalagin, a content of (20.3±0.06) mg / kg of ellagic acid, a content of (17.55±0.07) mg / kg of quercetin, a content of (142.75±0.3) mg / kg of tocopherol, and a content of (195.4±0.22) mg / kg of lignan.

3. The edible blended oil according to claim 1 or 2, characterized in that: The edible blended oil comprises: an oleic acid content of (36.18±0.21) to (38.25±0.15)%, a punicic acid content of (4.0±0.05) to (6.0±0.05)%, a spicric acid content of (0.65±0.04) to (0.98±0.04)%, a linolenic acid content of (7±0.27) to (8.25±0.12)%, an EPA content of (1±0.04) to (1.5±0.04)%, and a DHA content of (0.75±0.03) to (1.12±0.03)%.

4. The edible blended oil according to claim 3, characterized in that: The oleic acid content is 38.3%, the punicic acid content is 4%, the saponin acid content is 0.65%, the linolenic acid content is 7%, the EPA content is 1.5%, and the DHA content is 1.12%.

5. The method for preparing the edible blended oil according to any one of claims 1 to 4, characterized in that: The method comprises the steps of mixing medium chain triglyceride, olive oil, fish oil, pomegranate seed oil, torreya grandis seed oil and linseed oil, stirring and filtering to obtain the edible blended oil.

6. The method for preparing edible blended oil according to claim 5, characterized in that: The stirring is performed at room temperature, for 20 to 30 minutes, at a speed of 60 to 80 r / min.

7. The method for preparing edible blended oil according to claim 5, characterized in that: The filtration is performed through a 400-mesh net.

Images